Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

A new survey reveals that 80% of Americans not enrolled in Medicare are afraid that Medicare will not be there when they are eligible to enroll.

Of 14 metabolites identified, 2 appeared to have “robust” causal relationships with idiopathic pulmonary fibrosis.

Many patients value conversations with their rheumatologists and oncologists more than just reading information from a website.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial ...

US ovarian cancer mortality rates declined from 1999 to 2020, but significant disparities remain across age, race, and geographic regions, highlighting the need for targeted public health efforts.

Older patients with small cell lung cancer and significant weight loss were more likely to experience dose interruptions than ...

Mirima Freimer, MD, delves into potential reasons behind the longer-term efficacy of zilucoplan and also speaks to the treatment’s safety profile.

Panelists discuss how transitioning patients from intravenous (IV) to subcutaneous (SubQ) therapies demands a coordinated, multidisciplinary approach—integrating clinical judgment, electronic medical ...

Panelists discuss that improving outcomes for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) requires multifaceted efforts including developing ...

Panelists discuss the shift toward patient-centered outcomes in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis treatment, emphasizing quality of life and symptom relief alongside ...